TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1997887
Drug: Radiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and a combination of chloroethylnitrosoureas and tegafur (300 mg/m2, daily)
Study: 20171481
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine
Study: 28722815
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL Aqua)
Study: 28722815
Drug: Naloxone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.2 mg/mL)
Study: 12734746
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (GH) at a dosage of 28 IU/m² per week for 6 months
Study: 12734746
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (GH) at a dosage of 28 IU/m² per week for 2 years
Study: 12734746
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (GH) at a dosage of 28 IU/m² per week for 4 years
Study: 10374214
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day tibolone continuously (n = 27; group T)
Study: 10374214
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day conjugated equine estrogen plus 2.5 mg/day of medroxyprogesterone (n = 25; group E-P)
Study: 10374214
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 24; group C)
Study: 2071784
Drug: Standardized orchard
Normalized name: Standardized orchard grass pollen
DrugBank: Dactylis glomerata pollen (DB10379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized orchard grass-pollen extract or standardized mixed-pollen extract (specific immunotherapy)
Study: 25471256
Drug: Vestibular rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular rehabilitation (group-based sessions conducted twice a week for 9 weeks)
Study: 22009807
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 1µg/kg administered three minutes before anesthesia induction
Study: 22009807
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 1µg/kg
Study: 19147455
Drug: Strict metabolic
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict metabolic control by insulin (I-group; n = 21)
Study: 19147455
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose lowering agents (O-group; n = 18)
Study: 15150623
Drug: Epidoxorubicin (E)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidoxorubicin (E) 80 mg/m² + Paclitaxel (T) 175 mg/m² (3 h infusion), every 21 days for 4-6 cycles
Study: 15150623
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m² (3 h infusion), every 21 days for 4-6 cycles
Study: 7902200
Drug: Neuroleptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic treatment teaching module applied three hours per week for two to three months
Study: 7902200
Drug: Neuroleptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic treatment teaching module
Study: 25794779
Drug: Amoxicillin (or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (or clindamycin) given from one hour before operation until 3 days postoperatively
Study: 25794779
Drug: Placebo given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given at the same time as the antibiotic
Study: 15126920
Drug: Oral methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine (100 mg/kg)
Study: 20396717
Drug: nonsteroidal antiinflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: nonsteroidal antiinflammatory preparations (NSAIDs)
Study: 11434828
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/d (secondary prevention cohort)
Study: 31965772
Drug: Famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 500 mg
Study: 2337520
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% tretinoin
Study: 9519139
Drug: Placebo base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo base cream
Study: 504666
Drug: 10 mg/50
Normalized name: Nipride RTU, 10 mg/50 mL-NaCl 0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/50 ml of Xylocaine
Study: 504666
Drug: 20 mg/50
Normalized name: Pepcid, 20 mg/50 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/50 ml of Xylocaine
Study: 23437789
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of red grape seed extract (RGSE)
Study: 19909499
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (one gram twice daily)
Study: 14644401
Drug: Insulin resistant
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistant subjects (IR)
Study: 14644401
Drug: Insulin sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitive subjects (Control)
Study: 6654626
Drug: Antacids plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids plus vitamin A (3 X 50,000 U orally)
Study: 6654626
Drug: Antacids plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids plus vitamin A plus cyproheptadine (3 X 4 mg orally)
Study: 6654626
Drug: Antacids only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids only
Study: 3511867
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CAT scans and biochemical tests
Study: 24925372
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg enoxaparin subcutaneously once daily
Study: 24925372
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg enoxaparin subcutaneously once daily
Study: 19449224
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) nasal spray, 200 microg for 3 months
Study: 15632339
Drug: Lowest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest quartile of control PIGF concentrations (<118 pg/mL)
Study: 12745724
Drug: Oral ephedrine
Normalized name: ephedrine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ephedrine 50 mg
Study: 12745724
Drug: Supplemental ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplemental ephedrine (3 mg)
Study: 11206014
Drug: Pharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic therapy to passivate plaque for at least 24 hours
Study: 11206014
Drug: Low-molecular-weight heparins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors
Study: 8645662
Drug: Soluble ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble ibuprofen 200 mg
Study: 8645662
Drug: Soluble ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble ibuprofen 600 mg
Study: 8645662
Drug: Ibuprofen tablets
Normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen tablets 200 mg
Study: 1346564
Drug: Clonidine, 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine, 0.075 mg orally, at baseline and after 2 hours if heart rate did not decrease by at least 20%
Study: 2719902
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg three times daily and 400 mg at night)
Study: 28556506
Drug: Fosdagrocorat 10
Normalized name: Fosdagrocorat
DrugBank: Fosdagrocorat (DB12198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosdagrocorat 10 mg
Study: 28556506
Drug: Fosdagrocorat 15
Normalized name: Fosdagrocorat
DrugBank: Fosdagrocorat (DB12198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosdagrocorat 15 mg
Study: 31168411
Drug: Fosdagrocorat 1
Normalized name: Fosdagrocorat
DrugBank: Fosdagrocorat (DB12198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosdagrocorat 1 mg, 5 mg, 10 mg
Study: 31168411
Drug: Fosdagrocorat 1
Normalized name: Fosdagrocorat
DrugBank: Fosdagrocorat (DB12198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosdagrocorat 1 mg, 5 mg, 10 mg, 15 mg
Study: 28556506
Drug: Prednisone 10
Normalized name: prednisone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 10 mg
Study: 28556506
Drug: Prednisone 5
Normalized name: prednisone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 5 mg
Study: 22365462
Drug: Cool Teens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cool Teens program (12-week computerized cognitive-behavioral therapy program for anxiety management)
Study: 19481279
Drug: Simvastatin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (low dose: 5 mg)
Study: 19481279
Drug: Simvastatin (moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (moderate dose: 10 mg)
Study: 16177674
Drug: Rate control
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate control (Digoxin and beta-blocker)
Study: 16177674
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral anticoagulation
Study: 8843283
Drug: Crystalline formulation
Normalized name: Mesembryanthemum crystallinum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalline formulation of erythromycin ethylsuccinate (CEE) at 1,000 mg every 12 h
Study: 8843283
Drug: Amorphous formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorphous formulation of erythromycin ethylsuccinate (AEE) at 500 mg every 12 h
Study: 6233398
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg intramuscular (IM) MPA (high dose) daily for four weeks
Study: 6233398
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg IM MPA (low dose) twice weekly for four weeks
Study: 24272917
Drug: Romosozumab 1
Normalized name: romosozumab 105 mg/1.17 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romosozumab 1 mg/kg Q2W
Study: 24272917
Drug: Romosozumab 2
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 2 mg/kg Q2W
Study: 24272917
Drug: Romosozumab 2
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 2 mg/kg Q4W
Study: 24272917
Drug: Romosozumab 3
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 3 mg/kg Q4W
Study: 18574390
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 20 mg tid for 3 months (n = 19)
Study: 7778179
Drug: Theophylline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (600 mg/day in 2 doses)
Study: 2190460
Drug: Isosorbide-5-mononitrate, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate, 20 mg 3 times daily
Study: 358755
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) 200 mg
Study: 358755
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) 400 mg
Study: 358755
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) 600 mg
Study: 28072709
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) - bolus dose of 30 mg/kg i.v, maintenance dosage of 2 mg/kg/h
Study: 19796051
Drug: Sildenafil (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25, 50, or 100 mg)
Study: 17063108
Drug: Topical pharyngeal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pharyngeal anesthesia with lidocaine throat spray
Study: 17063108
Drug: Placebo sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sedation and placebo throat spray
Study: 19231302
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous cannula nor throat spray (control group)
Study: 9385861
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg bd for 3 months
Study: 7974316
Drug: Oxygen at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen at 2 l/min via a mask
Study: 7974316
Drug: Control walk
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control walk using a sham circuit (breathing air via an oxygen mask at 2 l/min from an unlabelled cylinder)
Study: 6990875
Drug: Aerosol administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosol administration of fenoterol
Study: 1162529
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of fenoterol
Study: 30741567
Drug: Crocus sativus
Normalized name: CROCUS SATIVUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocus sativus (saffron) 20-30 mg/d (20 mg/d for <30 kg and 30 mg/d for >30 kg)
Study: 30741567
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 20-30 mg/d (20 mg/d for <30 kg and 30 mg/d for >30 kg)
Study: 23630039
Drug: Beta-alanine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (80 mg·kg‐1BM·day‐1)
Study: 19743907
Drug: Unemployed, currently
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unemployed, currently unmarried, obese, never pregnant, and ever use of oral contraceptive
Study: 9193433
Drug: Low-dose ramipril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ramipril (0.625 mg)
Study: 11174337
Drug: Full-dose ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose ramipril (10 mg)
Study: 3890604
Drug: Morphine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (standard analgesic)
Study: 30170533
Drug: Vaginal gels
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gels
Study: 30170533
Drug: Monthly product
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly product use
Study: 26872219
Drug: Misoprostol treatment
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol treatment by midwives
Study: 26872219
Drug: Misoprostol treatment
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol treatment by physicians
Study: 23225854
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of borneol (30.0 mg/kg)
Study: 23225854
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of borneol (30.0 mg/kg)
Study: 23225854
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of borneol (30.0 mg/kg)
Study: 18801829
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered oxytocin (24 UI)
Study: 16035378
Drug: Amoxicillin 875
Normalized name: amoxicillin 875 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 875 mg tablets (test formulation)
Study: 16035378
Drug: Amoxil BD
Normalized name: Amoxi Drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxil BD 875 mg tablets (reference formulation)
Study: 27928851
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg intravenous parecoxib
Study: 18203048
Drug: Amisulpride 400
Normalized name: amisulpride 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 400 mg/day
Study: 9298518
Drug: Amisulpride 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 800 mg/day
Study: 9696517
Drug: Amisulpride 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 1200 mg/day
Study: 9167505
Drug: Haloperidol 16
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 16 mg/day
Study: 7654731
Drug: Lovastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (10 mg/day)
Study: 11545549
Drug: Bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (400 mg/day)
Study: 2127139
Drug: n-3 PUFA-rich
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA-rich fish oil diet (2 g/day)
Study: 2127139
Drug: n-3 PUFA-rich
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA-rich fish oil diet (6 g/day)
Study: 371629
Drug: Aspirin (3904
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3904 mg daily for 1 week)
Study: 371629
Drug: Fenoprofen (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoprofen (2400 mg daily for 1 week)
Study: 26032729
Drug: Tailored delirium
Normalized name: Octinoxate 0.068 g in 1 g TOPICAL PASTE [Esika PRO HD LONGWEAR LONG-LASTING HIGH-DEFINITION COLOR SPF 20 FUCSIA DELIRIO - PINK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored delirium prevention protocol applied daily for the first 7 days of ICU hospitalization
Study: 27683610
Drug: Inhaled treprostinil
Normalized name: treprostinil Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled treprostinil
Study: 19691461
Drug: Other antiviral
Normalized name: Other antivirals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antiviral agents
Study: 19691461
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of shingles
Study: 19691461
Drug: Different classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different classes of drugs for post-herpetic neuralgia
Study: 3145357
Drug: VACA chemotherapy
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VACA chemotherapy (vincristine, actinomycin D, cyclophosphamide, and adriamycin) with local control via surgery and/or radiation
Study: 3145357
Drug: VAIA chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAIA chemotherapy (high doses of ifosfamide with mesna uroprotection)
Study: 30566760
Drug: Curcumin (CUR)
DrugBank: Curcumin sulfate (DB14635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (CUR) 180 mg/d for 7 days before exercise
Study: 30566760
Drug: Curcumin (CUR)
DrugBank: Curcumin sulfate (DB14635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (CUR) 180 mg/d for 7 days after exercise
Study: 29092078
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite 300 µg/d po + Methimazole (MMI)
Study: 23811682
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified eicosapentaenoic acid (EPA) 1,800 mg/day for 6 months
Study: 20668324
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no EPA treatment)
Study: 18199388
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (2.9 g n-3 LCPUFA/d)
Study: 1676932
Drug: MK-458 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-458 (up to 60 mg per day)
Study: 30762806
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g single dose of azithromycin
Study: 30762806
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg doxycycline twice daily for 7 days
Study: 29180640
Drug: CSII combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII combined with metformin therapy
Study: 20740300
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg oral dose) with ketoconazole (400 mg/day for 7 days)
Study: 20740300
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg oral dose) alone
Study: 12011966
Drug: HR (Paroven-Venoruton;
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR (Paroven-Venoruton; 0-(beta-hydroxyethyl)-rutosides) 2 g/day for 8 weeks
Study: 85988
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (E.A.C.A.), 36 g/day
Study: 85988
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antifibrinolytic drug)
Study: 27081739
Drug: Everolimus plus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus plus reduced-dose tacrolimus (EVR + rTAC)
Study: 23307042
Drug: LA group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA group: lansoprazole (LPZ) 30 mg 4 times a day + amoxicillin (AMPC) 500 mg 4 times a day for two weeks
Study: 23307042
Drug: LAL group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAL group: LPZ 30 mg twice a day + AMPC 750 mg twice a day + levofloxacin (LVFX) 300 mg twice a day for one week